A Green Sign – Lifestyle
Author:
4Bio Capital
4BIO Capital leads oversubscribed £61 million ($83m) Series A financing of Cytospire Therapeutics
May 5, 2026
4BIO Capital portfolio company Ray Therapeutics announces upsized and oversubscribed $125 Million Series B financing for vision restoration treatments
April 21, 2026
4BIO Capital strengthens investment leadership with appointment of Therese Liechtenstein as Partner and Tetsu Maruyama as Venture Partner
March 30, 2026